Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) EBT (2019 - 2025)

Historic EBT for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$112.7 million.

  • Beam Therapeutics' EBT fell 1661.36% to -$112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.8 million, marking a year-over-year decrease of 20544.55%. This contributed to the annual value of -$376.7 million for FY2024, which is 18720.66% down from last year.
  • Latest data reveals that Beam Therapeutics reported EBT of -$112.7 million as of Q3 2025, which was down 1661.36% from -$102.3 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' EBT ranged from a high of $144.2 million in Q4 2023 and a low of -$200.4 million during Q1 2021
  • Its 5-year average for EBT is -$76.1 million, with a median of -$89.0 million in 2023.
  • As far as peak fluctuations go, Beam Therapeutics' EBT plummeted by 62193.24% in 2021, and later soared by 48598.89% in 2023.
  • Beam Therapeutics' EBT (Quarter) stood at -$64.7 million in 2021, then soared by 42.28% to -$37.3 million in 2022, then soared by 485.99% to $144.2 million in 2023, then plummeted by 162.67% to -$90.4 million in 2024, then dropped by 24.76% to -$112.7 million in 2025.
  • Its EBT stands at -$112.7 million for Q3 2025, versus -$102.3 million for Q2 2025 and -$109.4 million for Q1 2025.